Advances in receptor conformation research: The quest for functionally selective conformations focusing on the β2-adrenoceptor

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5477-5488

  Woo, Anthony Yiu Ho ^a   Song, Ying ^a   Zhu, Weizhong ^a   Xiao, Rui Ping ^a,b  

^a PEKING UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LIGAND;

BINDING AFFINITY; CONFORMATIONAL TRANSITION; FLUORESCENCE SPECTROSCOPY; HUMAN; HYDROGEN BOND; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE MOLECULE FORCE SPECTROSCOPY; SITE DIRECTED MUTAGENESIS; SPECTROSCOPY; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; METABOLISM;

ADRENERGIC BETA-ANTAGONISTS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 84949534449     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13049     Document Type: Review

References (114)

1. Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI, (2004). Beneficial effects of chronic pharmacological manipulation of β-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 110: 1083-1090.
2. 1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10: 289-296.
3. 1AR blocker in dilated cardiomyopathy post-myocardial infarction. J Pharmacol Exp Ther 325: 491-499.
4. Ahmet I, Morrell C, Lakatta EG, Talan MI, (2009). Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 331: 178-185.
5. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The concise guide to Pharmacology 2013/14: G protein-coupled receptors. Br J Pharmacol 280: 1459-1581.
6. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The concise guide to Pharmacology 2013/14: Enzymes. Br J Pharmacol 280: 1797-1867.
7. Audet N, Gales C, Archer-Lahlou E, Vallieres M, Schiller PW, Bouvier M, et al. (2008). Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem 283: 15078-15088.
8. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100: 11406-11411.
9. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, et al. (2003). β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci U S A 100: 940-945.
10. Baneres JL, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaert J, (2005). Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J Biol Chem 280: 20253-20260.
11. Beigi F, Bertucci C, Zhu W, Chakir K, Wainer IW, Xiao RP, et al. (2006). Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol. Chirality 18: 822-827.
12. Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schioth HB, (2006). Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88: 263-273.
13. Bock A, Merten N, Schrage R, Dallanoce C, Batz J, Klockner J, et al. (2012). The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 3: 1044.
14. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, et al. (2010). Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463: 108-112.
15. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, et al. (1995). Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor. Nature 374: 272-276.
16. Calebiro D, Rieken F, Wagner J, Sungkaworn T, Zabel U, Borzi A, et al. (2013). Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A 110: 743-748.
17. Castro M, Nikolaev VO, Palm D, Lohse MJ, Vilardaga JP, (2005). Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A 102: 16084-16089.
18. Chakir K, Depry C, Dimaano VL, Zhu WZ, Vanderheyden M, Bartunek J, et al. (2011). Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med 3: 100ra188.
19. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, et al. (2012). Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D(2) receptor agonists. J Med Chem 55: 7141-7153.
20. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
21. Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, et al. (2013). Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A 110: 18232-18237.
22. Costa T, Herz A, (1989). Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 86: 7321-7325.
23. Daaka Y, Luttrell LM, Lefkowitz RJ, (1997). Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91.
24. Damian M, Martin A, Mesnier D, Pin JP, Baneres JL, (2006). Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J 25: 5693-5702.
25. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, Bunnett NW, (2000). The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci U S A 97: 11086-11091.
26. DeWire SM, Violin JD, (2011). Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109: 205-216.
27. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ, (2008). beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283: 5669-5676.
28. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ, (2010). Ligand-directed signalling at b-adrenoceptors. Br J Pharmacol 159: 1022-1038.
29. Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, et al. (2014). Molecular control of delta-opioid receptor signalling. Nature 506: 191-196.
30. Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB, (2012). Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol 81: 820-831.
31. Galandrin S, Bouvier M, (2006). Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70: 1575-1584.
32. Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M, (2008). Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol 74: 162-172.
33. Gales C, Van Durm JJ, Schaak S, Pontier S, Percherancier Y, Audet M, et al. (2006). Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13: 778-786.
34. Gether U, Lin S, Kobilka BK, (1995). Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 270: 28268-28275.
35. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK, (1997). Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 16: 6737-6747.
36. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK, (2001a). Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A 98: 5997-6002.
37. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, et al. (2001b). Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
38. Granier S, Kim S, Shafer AM, Ratnala VR, Fung JJ, Zare RN, et al. (2007). Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem 282: 13895-13905.
39. Head BP, Patel HH, Roth DM, Lai NC, Niesman IR, Farquhar MG, et al. (2005). G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem 280: 31036-31044.
40. Hoffmann C, Zurn A, Bunemann M, Lohse MJ, (2008). Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol 153 (Suppl. 1): S358-S366.
41. Jozwiak K, Khalid C, Tanga MJ, Berzetei-Gurske I, Jimenez L, Kozocas JA, et al. (2007). Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem 50: 2903-2915.
42. Jozwiak K, Woo AY, Tanga MJ, Toll L, Jimenez L, Kozocas JA, et al. (2010). Comparative molecular field analysis of fenoterol derivatives: a platform towards highly selective and effective beta(2)-adrenergic receptor agonists. Bioorg Med Chem 18: 728-736.
43. Kahsai AW, Xiao K, Rajagopal S, Ahn S, Shukla AK, Sun J, et al. (2011). Multiple ligand-specific conformations of the beta2-adrenergic receptor. Nat Chem Biol 7: 692-700.
44. Kawamura S, Gerstung M, Colozo AT, Helenius J, Maeda A, Beerenwinkel N, et al. (2013). Kinetic, energetic, and mechanical differences between dark-state rhodopsin and opsin. Structure 21: 426-437.
45. Kenakin T, (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
46. Kenakin T, (2006) A Pharmacology Primer-Theory, Application and Methods, 2nd edn. Academic Press: London.
47. Kenakin T, (2007). Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28: 407-415.
48. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
49. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, et al. (2008). Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A 105: 14555-14560.
50. Kim TH, Chung KY, Manglik A, Hansen AL, Dror RO, Mildorf TJ, et al. (2013). The role of ligands on the equilibria between functional states of a G protein-coupled receptor. J Am Chem Soc 135: 9465-9474.
51. Kobilka BK, Deupi X, (2007). Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28: 397-406.
52. Kofuku Y, Ueda T, Okude J, Shiraishi Y, Kondo K, Maeda M, et al. (2012). Efficacy of the beta(2)-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. Nat Commun 3: 1045.
53. Lefkowitz RJ, (1998). G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677-18680.
54. Lefkowitz RJ, Shenoy SK, (2005). Transduction of receptor signals by β-arrestins. Science 308: 512-517.
55. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K, (2012). Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science 335: 1106-1110.
56. Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Vilardaga JP, Bunemann M, (2008). Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol 153 (Suppl. 1): S125-S132.
57. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. (1999). Beta-arrestin-dependent formation of Beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
58. Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, et al. (2001). Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci U S A 98: 2449-2554.
59. Malik RU, Ritt M, DeVree BT, Neubig RR, Sunahara RK, Sivaramakrishnan S, (2013). Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells. J Biol Chem 288: 17167-17178.
60. Mary S, Damian M, Louet M, Floquet N, Fehrentz JA, Marie J, et al. (2012). Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc Natl Acad Sci U S A 109: 8304-8309.
61. Maudsley S, Martin B, Luttrell LM, (2005). The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther 314: 485-494.
62. Moukhametzianov R, Warne T, Edwards PC, Serrano-Vega MJ, Leslie AG, Tate CG, et al. (2011). Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor. Proc Natl Acad Sci U S A 108: 8228-8232.
63. Negishi M, Sugimoto Y, Namba T, Irie A, Narumiya S, Ichikawa A, (1995). Signal transductions of three isoforms of mouse prostaglandin E receptor EP3 subtype. Adv Prostaglandin Thromboxane Leukot Res 23: 255-257.
64. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S, et al. (2011). Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci Signal 4: ra51.
65. Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, et al. (2013). The dynamic process of beta(2)-adrenergic receptor activation. Cell 152: 532-542.
66. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
67. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
68. Plazinska A, Kolinski M, Wainer IW, Jozwiak K, (2013). Molecular interactions between fenoterol stereoisomers and derivatives and the beta(2)-adrenergic receptor binding site studied by docking and molecular dynamics simulations. J Mol Model 19: 4919-4930.
69. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, et al. (2012). Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc Natl Acad Sci U S A 109: 6733-6738.
70. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
71. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
72. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al. (2011a). Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 469: 175-180.
73. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. (2011b). Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
74. Reiner S, Ambrosio M, Hoffmann C, Lohse MJ, (2010). Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem 285: 36188-36198.
75. Ren XR, Reiter E, Ahn S, Kim J, Chen W, Lefkowitz RJ, (2005). Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A 102: 1448-1453.
76. Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, et al. (2013). Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. Nature 502: 575-579.
77. Rochais F, Vilardaga JP, Nikolaev VO, Bunemann M, Lohse MJ, Engelhardt S, (2007). Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117: 229-235.
78. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273.
79. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, et al. (2011). Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 469: 236-240.
80. Seifert R, Gether U, Wenzel-Seifert K, Kobilka BK, (1999). Effects of guanine, inosine, and xanthine nucleotides on beta(2)-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 56: 348-358.
81. Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK, (2001). Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297: 1218-1226.
82. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. (2006). β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem 281: 1261-1273.
83. Shonberg J, Herenbrink CK, Lopez L, Christopoulos A, Scammells PJ, Capuano B, et al. (2013). A structure-activity analysis of biased agonism at the dopamine D2 receptor. J Med Chem 56: 9199-9221.
84. Shukla AK, Westfield GH, Xiao K, Reis RI, Huang LY, Tripathi-Shukla P, et al. (2014). Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 512: 218-222.
85. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK, (2004). Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem 279: 686-691.
86. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, et al. (2005). Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280: 22165-22171.
87. Tateyama M, Kubo Y, (2006). Dual signaling is differentially activated by different active states of the metabotropic glutamate receptor 1alpha. Proc Natl Acad Sci U S A 103: 1124-1128.
88. Tateyama M, Abe H, Nakata H, Saito O, Kubo Y, (2004). Ligand-induced rearrangement of the dimeric metabotropic glutamate receptor 1alpha. Nat Struct Mol Biol 11: 637-642.
89. Tschammer N, Bollinger S, Kenakin T, Gmeiner P, (2011). Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Mol Pharmacol 79: 575-585.
90. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
91. Vilardaga JP, Frank M, Krasel C, Dees C, Nissenson RA, Lohse MJ, (2001). Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein. J Biol Chem 276: 33435-33443.
92. Violin JD, Lefkowitz RJ, (2007). Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28: 416-422.
93. Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, et al. (2010). Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132: 11443-11445.
94. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, et al. (2013). Structural features for functional selectivity at serotonin receptors. Science 340: 615-619.
95. Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, et al. (2013). Structural basis for molecular recognition at serotonin receptors. Science 340: 610-614.
96. Wang J, (2014). Biased ligand bonds to make right calls-laboratory of signal transduction reveals molecular mechanism for functional selectivity of GPCR. Sci China Life Sci 57: 957-958.
97. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al. (2008). Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
98. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AG, et al. (2011). The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 469: 241-244.
99. Warne T, Edwards PC, Leslie AG, Tate CG, (2012). Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20: 841-849.
100. West GM, Chien EY, Katritch V, Gatchalian J, Chalmers MJ, Stevens RC, et al. (2011). Ligand-dependent perturbation of the conformational ensemble for the GPCR beta2 adrenergic receptor revealed by HDX. Structure 19: 1424-1432.
101. Wiens BL, Nelson CS, Neve KA, (1998). Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. Mol Pharmacol 54: 435-444.
102. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al. (2007). A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 104: 16657-16662.
103. Woo AY, Xiao RP, (2012). β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin 33: 335-341.
104. Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW, et al. (2009). Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 75: 158-165.
105. Woo AY, Jozwiak K, Toll L, Tanga MJ, Kozocas JA, Jimenez L, et al. (2014). Tyrosine 308 is necessary for ligand-directed Gs-biased signaling of beta2-adrenoceptor. J Biol Chem 289: 19351-19363.
106. 2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol DOI: 10.1111/bph.12965.
107. Xiang Y, Kobilka BK, (2003). The PDZ-binding motif of the β2-adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes. Proc Natl Acad Sci U S A 100: 10776-10781.
108. Xiao RP, Ji X, Lakatta EG, (1995). Functional coupling of the beta 2-adrenoceptor to a Pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 47: 322-329.
109. i proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84: 43-52.
110. Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, et al. (2003). Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108: 1633-1639.
111. Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, et al. (2006). Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol 2: 417-422.
112. Yao XJ, Velez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, Deupi X, et al. (2009). The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A 106: 9501-9506.
113. Zocher M, Fung JJ, Kobilka BK, Muller DJ, (2012). Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor. Structure 20: 1391-1402.
114. Zurn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, Hoffmann C, (2009). Fluorescence resonance energy transfer analysis of alpha 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol 75: 534-541.